Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population

BACKGROUND: Trastuzumab emtansine (T-DM1) has been approved since 2013 for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who had received trastuzumab (Tmab) and taxane. However, no clinical trial has evaluated the efficacy of T-DM1 in those who...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Breast Cancer
Glavni autori: Noda-Narita, Shoko, Shimomura, Akihiko, Kawachi, Asuka, Sumiyoshi-Okuma, Hitomi, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Yonemori, Kan, Shimizu, Chikako, Fujiwara, Yasuhiro, Tamura, Kenji
Format: Artigo
Jezik:Inglês
Izdano: Springer Japan 2019
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6570684/
https://ncbi.nlm.nih.gov/pubmed/30737616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-019-00949-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items